Burden and impact of co-morbidity and frailty in patients with RMDs in Europe: a multi-national analysis of big healthcare data


The Observational and Medical Outcomes Partnerships (OMOP) common data model (CDM) provides a framework for standardising observational health data. Multi-database studies can then be performed without a need to pool patient-level data across network sites, and with only aggregate results shared.

In this project we are mapping data from biologic registries to the OMOP CDM. This will then allow for an assessment of comorbidity in people with severe RA in Europe, and provide the basis for further collaborative projects.

Facts and Figures

Project Lead
D Prieto-Alhambra
Autonomous University of Barcelona
FOREUM research grant: € 200.000
Publications: www.foreum.org/comorbidities

Meet the Team


To map national biologic registry data collected from different European countries to the OMOP CDM. In particular, five  biologic registries are currently being mapped to the OMOP CDM: 1) the Czech biologics register (ATTRA), 2) Registro Español de Acontecimientos Adversos de Terapias Biológicas en Enfermedades Reumáticas (BIOBADASER), 3) British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA), 4) German biologics register ‘Rheumatoid arthritis observation of biologic therapy’ (RABBIT), and 5) Swiss register ’Swiss Clinical Quality Management in Rheumatic Diseases’ (SCQM).

Subsequently, to summarise the available data on comorbidities across these registries.

Patient Voice

Patient research partners are being involved as research partners throughout this project.

Project Map